Bicara Therapeutics Inc. SEC filings BCAX

Bicara Therapeutics Inc. has 263 filings in SEC EDGAR's recent list, going back to Jun 10, 2024. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Apr 21, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 25, 2026 (material agreement). The company's fiscal year ends on December 31.

Bicara Therapeutics Inc. SEC filings
Form Description Filed Period
S-8 Employee stock plan registration Aug 11, 2026 —
S-8 Employee stock plan registration Mar 31, 2026 —
424B5 Prospectus supplement Feb 26, 2026 —
FWP Free writing prospectus Feb 25, 2026 —
424B5 Prospectus supplement Feb 24, 2026 —
424B5 Prospectus supplement Nov 26, 2025 —
S-3 Shelf registration Oct 3, 2025 —
S-8 Employee stock plan registration Mar 28, 2025 —
S-8 Employee stock plan registration Sep 13, 2024 —
424B4 Prospectus Sep 13, 2024 —
S-1MEF Filing Sep 12, 2024 —
S-1/A Amended registration statement Sep 11, 2024 —
S-1/A Amended registration statement Sep 6, 2024 —
S-1/A Amended registration statement Sep 3, 2024 —
S-1 Registration statement Aug 22, 2024 —

Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
BCAX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
, Emerging growth company
SEC CIK
2023658

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.